Biologics Manufacturing Germany 2024

Germany's biopharmaceutical market has witnessed remarkable growth in recent years driven by significant advancements in the major European pharmaceutical market and ranked the fourth largest worldwide. These include increased investments in R&D, the expansion of biotechnology infrastructure and capacity, and a supportive regulatory environment. The German biologics market is projected to continue its upward trajectory, driven by rising demand for innovative biologic therapies across therapeutic areas such as oncology, autoimmune diseases, and rare disorders. In addition to local industry players like Bayer and Boehringer Ingelheim, many international pharmaceutical companies – including, for instance, GlaxoSmithKline, Pfizer, Roche, Sanofi and Takeda – operate production facilities in Germany.

The Biologics World Germany 2024 Conference stands as a premier gathering of biopharmaceutical professionals, with the primary goal of fostering collaboration, innovation, and knowledge exchange within the dynamic landscape of biologics R&D and manufacturing. Specifically focusing on Germany's burgeoning biopharmaceutical sector, this conference serves as a catalyst for bringing together key stakeholders, thought leaders, and industry experts to explore the latest advancements and challenges shaping the future of biologics development and production.

At the Biologics World Germany 2024, key topics such as best practices in biologics R&D, clinical research & trials, advancements in bioprocess upstream optimization and technology innovations, downstream processing cost-cutting strategies, continuous manufacturing and single-use systems, regulatory considerations, quality & analytics as well as commercialization strategies will be highlighted to address the evolving landscape of biopharmaceutical R&D and manufacturing. By bringing together industry leaders, researchers, and stakeholders, this conference aims to accelerate advancements in biologics development, production, and commercialization, further strengthening Germany's position as a global leader in the biopharmaceutical arena.